Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Ankylosing Spondylitis (AS) Market Outlook

Thelansis’s “Ankylosing Spondylitis (AS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ankylosing Spondylitis (AS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ankylosing Spondylitis (AS) Overview

Ankylosing spondylitis (AS) is a type of arthritis primarily impacting the spine, potentially affecting other joints as well. It results in inflammation of the spinal vertebrae, leading to persistent and severe pain. In advanced stages, this inflammation can cause ankylosis, which is the formation of new bone in the spine, resulting in spine sections becoming fused and immobile. Additionally, AS can bring about inflammation, pain, and stiffness in various body parts, including the shoulders, hips, ribs, heels, and small joints of the hands and feet. On rare occasions, it can involve the eyes, known as iritis or uveitis, and affect the lungs and heart. A distinctive characteristic of ankylosing spondylitis is its impact on the sacroiliac (SI) joints, located at the spine’s base, where it connects with the pelvis. Although symptoms generally manifest in late adolescence or early adulthood, typically between the ages of 17 and 45, they can also emerge in childhood or later in life.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Ankylosing Spondylitis (AS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034